Stroke risk and NSAIDs: an Australian population-based study

Gillian E Caughey, Elizabeth E Roughead, Nicole Pratt, Graeme Killer and Andrew L Gilbert
Med J Aust 2011; 195 (9): 525-529. || doi: 10.5694/mja11.10055
  • Gillian E Caughey1
  • Elizabeth E Roughead1
  • Nicole Pratt1
  • Graeme Killer2
  • Andrew L Gilbert1

  • 1 Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, University of South Australia, Adelaide, SA.


Acknowledgements: Elizabeth Roughead was supported by an Australian Research Council Future Fellowship. We thank the Australian Department of Veterans’ Affairs for providing the data used in this study.

Competing interests:

Competing interests: No relevant disclosures.

  • 1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528.
  • 2. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102.
  • 3. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-1080.
  • 4. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-1644.
  • 5. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302-1308.
  • 6. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342; c7086.
  • 7. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 330: 1366.
  • 8. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-481.
  • 9. Haag MDM, Bos MJ, Hofman A, et al. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med 2008; 168: 1219-1224.
  • 10. Roumie CL, Mitchel EF Jr, Kaltenbach L, et al. Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke 2008; 39: 2037-2045.
  • 11. Fosbol EL, Folke F, Jacobsen S, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 2010; 3: 395-405.
  • 12. Gislason GH. Use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with increased risk of stroke among healthy people. European Society of Cardiology Congress; 2010 Aug 28-Sep 1; Stockholm, Sweden.
  • 13. Chang CH, Shau WY, Kuo CW, et al. Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study. Stroke 2010; 41: 1884-1890.
  • 14. Caughey GE, Cleland LG, Penglis PS, et al. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 2001; 167: 2831-2838.
  • 15. Chan CC, Reid CM, Aw TJ, et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009; 27: 2332-2341.
  • 16. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
  • 17. Patrono C, Patrignani P, García Rodríguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001; 108: 7-13.
  • 18. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563-7568.
  • 19. Australian Government Department of Veterans’ Affairs. Treatment population statistics. Quarterly report — June 2010. Canberra: DVA, 2010. (accessed Jun 2011).
  • 20. World Health Organization Collaborating Centre for Drug Statistics Methodology. Anatomical therapeutic chemical code classification index with defined daily doses. (accessed Sep 2011).
  • 21. Australian Government Department of Health and Ageing. Schedule of pharmaceutical benefits. PBS for health professionals. 2011. (accessed Jun 2011).
  • 22. National Centre for Classification in Health. International statistical classification of diseases and related health problems, 10th revision, Australian modification (ICD-10-AM). 7th ed. Sydney: NCCH, 2010.
  • 23. Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology 1996; 7: 478-484.
  • 24. Caughey GE, Roughead EE, Pratt N, et al. Increased risk of hip fracture in the elderly associated with prochlorperazine: is a prescribing cascade contributing? Pharmacoepidemiol Drug Saf 2010; 19: 977-982.
  • 25. Langton PE, Hankey GJ, Eikelboom JW. Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events. Med J Aust 2004; 181: 524-525.
  • 26. Australian Government Department of Health and Ageing. Australian statistics on medicine 2008. Canberra: Commonwealth of Australia, 2009.
  • 27. Caughey GE, Ramsay EN, Vitry AI, et al. Comorbid chronic diseases, discordant impact on mortality in the elderly; a 14 year longitudinal population study. J Epidemiol Community Health 2010; 64: 1036-1042.
  • 28. Corderoy A. Study links Voltaren and Nurofen to strokes. Sydney Morning Herald 2010; 14 Sep.
  • 29. Corderoy A. Painkiller linked to stroke. The Age (Melbourne) 2010; 14 Sep.
  • 30. Rose D. TGA monitoring drugs with stroke risk. MedConnect 2010; 14 Sep.
  • 31. Mangoni AA, Woodman RJ, Gaganis P, et al. Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. Br J Clin Pharmacol 2010; 69: 689-700.
  • 32. Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009; 2: 155-163.
  • 33. Solomon DH, Avorn J, Stürmer T, et al. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheumatism 2006; 54: 1378-1389.
  • 34. García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 52: 1628-1636.
  • 35. Australian Institute of Health and Welfare. Health care usage and costs. A comparison of veterans and war widows and widowers with the rest of the community. Canberra: AIHW, 2002. (AIHW Cat. No. PHE 42.)


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.